05/30/2025
5:25 PM | Neumora Therapeutics (Issuer)
Pinto Joshua (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2025
5:30 PM | Halawa Alaa (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2025
5:30 PM | Ho Maykin (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2025
5:30 PM | BERNS PAUL L (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2025
5:30 PM | Neumora Therapeutics (Issuer)
Piacquad David (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2025
5:30 PM | Aurora Daljit Singh (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2025
5:30 PM | Burow Kristina (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2025
5:30 PM | Fust Matthew K (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2025
5:30 PM | Duncan Jason (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2025
5:31 PM | Milligan Michael Lee (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/30/2025
4:21 PM | Neumora Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Get the Latest News and Ratings for NMRA and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
05/23/2025
3:42 PM | Neumora Therapeutics (Issuer)
Pinto Joshua (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/26/2025
11:15 PM | Neumora Therapeutics (Filer)
| Form EFFECT | |
03/12/2025
3:49 PM | Gosebruch Henry O (Reporting)
Neumora Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
03/03/2025
3:41 PM | Neumora Therapeutics (Filer)
| Form POS AM | |
03/03/2025
3:44 PM | Neumora Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/03/2025
6:32 AM | Neumora Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/03/2025
6:06 AM | Neumora Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/03/2025
6:12 AM | Neumora Therapeutics (Filer)
| Form POSASR | |
02/20/2025
4:11 PM | Neumora Therapeutics (Issuer)
Pinto Joshua (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/20/2025
4:12 PM | Lenz Robert A. (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/20/2025
4:13 PM | Aurora Daljit Singh (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/20/2025
4:14 PM | Milligan Michael Lee (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/20/2025
4:14 PM | BERNS PAUL L (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/18/2025
3:30 PM | Halawa Alaa (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/18/2025
3:30 PM | Duncan Jason (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/18/2025
3:30 PM | Neumora Therapeutics (Issuer)
Pinto Joshua (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/18/2025
3:30 PM | Milligan Michael Lee (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/18/2025
3:30 PM | Burow Kristina (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/18/2025
3:30 PM | Neumora Therapeutics (Issuer)
Piacquad David (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/18/2025
3:30 PM | Fust Matthew K (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/18/2025
3:30 PM | Aurora Daljit Singh (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/18/2025
3:30 PM | Ho Maykin (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/18/2025
3:30 PM | Lenz Robert A. (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/18/2025
3:30 PM | BERNS PAUL L (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/13/2025
3:51 PM | Neumora Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/13/2025
7:00 AM | Neumora Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/02/2025
6:10 AM | Neumora Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/27/2024
4:01 PM | BERNS PAUL L (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/22/2024
4:33 PM | ARCH Venture Fund XII, L.P. (Filed by)
Neumora Therapeutics (Subject)
| Form SC 13D/A | |
11/12/2024
6:17 AM | Neumora Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Revolutionary AI Tech Targets Early Diabetic Blindness Detection FDA Trial Underway (Ad) Tiny Stock, Massive Potential— this company’s AI platform is a game changer for healthcare! Discover how this tiny tech firm is using AI in healthcare |
10/18/2024
5:25 PM | Fust Matthew K (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/18/2024
3:01 PM | Fust Matthew K (Reporting)
Neumora Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/17/2024
3:26 PM | Fust Matthew K (Reporting)
Neumora Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/11/2024
3:10 PM | Lenz Robert A. (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/10/2024
3:30 PM | Lenz Robert A. (Reporting)
Neumora Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/09/2024
3:10 PM | Lenz Robert A. (Reporting)
Neumora Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/01/2024
4:22 PM | Neumora Therapeutics (Filer)
| Form S-3ASR | |
09/19/2024
3:35 PM | Lenz Robert A. (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/17/2024
3:37 PM | Lenz Robert A. (Reporting)
Neumora Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/13/2024
4:22 PM | Aurora Daljit Singh (Reporting)
Neumora Therapeutics (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
4:18 PM | Lenz Robert A. (Reporting)
Neumora Therapeutics (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/27/2024
4:58 PM | Neumora Therapeutics (Issuer)
Pinto Joshua (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/26/2024
5:17 PM | Neumora Therapeutics (Issuer)
Pinto Joshua (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/22/2024
8:48 AM | Neumora Therapeutics (Subject)
Pinto Joshua (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/06/2024
6:15 AM | Neumora Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
